nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—CYP3A5—Beclomethasone—psoriasis	0.0574	0.113	CbGbCtD
Aripiprazole—CYP2D6—Hydroxyurea—psoriasis	0.0267	0.0527	CbGbCtD
Aripiprazole—CYP3A7—Hydrocortisone—psoriasis	0.0245	0.0483	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0245	0.0483	CbGbCtD
Aripiprazole—CYP3A7—Cyclosporine—psoriasis	0.0231	0.0456	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0231	0.0456	CbGbCtD
Aripiprazole—CYP3A5—Mycophenolate mofetil—psoriasis	0.0229	0.0451	CbGbCtD
Aripiprazole—CYP3A4—Calcitriol—psoriasis	0.02	0.0394	CbGbCtD
Aripiprazole—CYP3A5—Hydrocortisone—psoriasis	0.0183	0.0362	CbGbCtD
Aripiprazole—CYP3A5—Cyclosporine—psoriasis	0.0173	0.0342	CbGbCtD
Aripiprazole—CYP2D6—Cholecalciferol—psoriasis	0.0162	0.0319	CbGbCtD
Aripiprazole—CYP3A4—Methoxsalen—psoriasis	0.0155	0.0307	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0152	0.03	CbGbCtD
Aripiprazole—CYP3A7—Dexamethasone—psoriasis	0.0152	0.03	CbGbCtD
Aripiprazole—ABCB1—Mycophenolate mofetil—psoriasis	0.0149	0.0294	CbGbCtD
Aripiprazole—ABCB1—Betamethasone—psoriasis	0.0128	0.0252	CbGbCtD
Aripiprazole—ABCB1—Prednisolone—psoriasis	0.0126	0.0249	CbGbCtD
Aripiprazole—ABCB1—Hydrocortisone—psoriasis	0.0119	0.0236	CbGbCtD
Aripiprazole—ABCB1—Prednisone—psoriasis	0.0119	0.0235	CbGbCtD
Aripiprazole—CYP3A5—Dexamethasone—psoriasis	0.0114	0.0225	CbGbCtD
Aripiprazole—ABCB1—Cyclosporine—psoriasis	0.0113	0.0223	CbGbCtD
Aripiprazole—CYP2D6—Cyclosporine—psoriasis	0.0106	0.021	CbGbCtD
Aripiprazole—CYP3A4—Cholecalciferol—psoriasis	0.0103	0.0203	CbGbCtD
Aripiprazole—CYP3A4—Mycophenolate mofetil—psoriasis	0.00891	0.0176	CbGbCtD
Aripiprazole—CYP3A4—Triamcinolone—psoriasis	0.00891	0.0176	CbGbCtD
Aripiprazole—CYP3A4—Betamethasone—psoriasis	0.00765	0.0151	CbGbCtD
Aripiprazole—CYP3A4—Prednisolone—psoriasis	0.00755	0.0149	CbGbCtD
Aripiprazole—ABCB1—Dexamethasone—psoriasis	0.00742	0.0147	CbGbCtD
Aripiprazole—CYP3A4—Hydrocortisone—psoriasis	0.00715	0.0141	CbGbCtD
Aripiprazole—CYP3A4—Prednisone—psoriasis	0.00713	0.0141	CbGbCtD
Aripiprazole—CYP2D6—Dexamethasone—psoriasis	0.007	0.0138	CbGbCtD
Aripiprazole—CYP3A4—Cyclosporine—psoriasis	0.00676	0.0133	CbGbCtD
Aripiprazole—ABCB1—Methotrexate—psoriasis	0.00597	0.0118	CbGbCtD
Aripiprazole—CYP3A4—Dexamethasone—psoriasis	0.00445	0.00879	CbGbCtD
Aripiprazole—Dermatitis—Mycophenolic acid—psoriasis	4.73e-05	0.00011	CcSEcCtD
Aripiprazole—Pain—Prednisolone—psoriasis	4.73e-05	0.00011	CcSEcCtD
Aripiprazole—Haemorrhage—Methotrexate—psoriasis	4.73e-05	0.00011	CcSEcCtD
Aripiprazole—Hepatitis—Methotrexate—psoriasis	4.73e-05	0.00011	CcSEcCtD
Aripiprazole—Urticaria—Mycophenolate mofetil—psoriasis	4.71e-05	0.00011	CcSEcCtD
Aripiprazole—Headache—Mycophenolic acid—psoriasis	4.71e-05	0.00011	CcSEcCtD
Aripiprazole—Decreased appetite—Hydrocortisone—psoriasis	4.7e-05	0.000109	CcSEcCtD
Aripiprazole—Pharyngitis—Methotrexate—psoriasis	4.69e-05	0.000109	CcSEcCtD
Aripiprazole—Abdominal pain—Mycophenolate mofetil—psoriasis	4.69e-05	0.000109	CcSEcCtD
Aripiprazole—Body temperature increased—Mycophenolate mofetil—psoriasis	4.69e-05	0.000109	CcSEcCtD
Aripiprazole—Urinary tract disorder—Methotrexate—psoriasis	4.67e-05	0.000109	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.66e-05	0.000109	CcSEcCtD
Aripiprazole—Fatigue—Hydrocortisone—psoriasis	4.66e-05	0.000108	CcSEcCtD
Aripiprazole—Vision blurred—Prednisone—psoriasis	4.64e-05	0.000108	CcSEcCtD
Aripiprazole—Urethral disorder—Methotrexate—psoriasis	4.63e-05	0.000108	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.63e-05	0.000108	CcSEcCtD
Aripiprazole—Pain—Hydrocortisone—psoriasis	4.62e-05	0.000108	CcSEcCtD
Aripiprazole—Oedema—Betamethasone—psoriasis	4.61e-05	0.000107	CcSEcCtD
Aripiprazole—Anaphylactic shock—Dexamethasone—psoriasis	4.61e-05	0.000107	CcSEcCtD
Aripiprazole—Anaphylactic shock—Betamethasone—psoriasis	4.61e-05	0.000107	CcSEcCtD
Aripiprazole—Oedema—Dexamethasone—psoriasis	4.61e-05	0.000107	CcSEcCtD
Aripiprazole—Insomnia—Triamcinolone—psoriasis	4.6e-05	0.000107	CcSEcCtD
Aripiprazole—Infection—Dexamethasone—psoriasis	4.58e-05	0.000107	CcSEcCtD
Aripiprazole—Infection—Betamethasone—psoriasis	4.58e-05	0.000107	CcSEcCtD
Aripiprazole—Ill-defined disorder—Prednisone—psoriasis	4.57e-05	0.000106	CcSEcCtD
Aripiprazole—Paraesthesia—Triamcinolone—psoriasis	4.57e-05	0.000106	CcSEcCtD
Aripiprazole—Feeling abnormal—Prednisolone—psoriasis	4.56e-05	0.000106	CcSEcCtD
Aripiprazole—Visual impairment—Methotrexate—psoriasis	4.56e-05	0.000106	CcSEcCtD
Aripiprazole—Anaemia—Prednisone—psoriasis	4.55e-05	0.000106	CcSEcCtD
Aripiprazole—Shock—Betamethasone—psoriasis	4.54e-05	0.000106	CcSEcCtD
Aripiprazole—Shock—Dexamethasone—psoriasis	4.54e-05	0.000106	CcSEcCtD
Aripiprazole—Dyspnoea—Triamcinolone—psoriasis	4.53e-05	0.000106	CcSEcCtD
Aripiprazole—Nervous system disorder—Dexamethasone—psoriasis	4.53e-05	0.000105	CcSEcCtD
Aripiprazole—Nervous system disorder—Betamethasone—psoriasis	4.53e-05	0.000105	CcSEcCtD
Aripiprazole—Agitation—Prednisone—psoriasis	4.53e-05	0.000105	CcSEcCtD
Aripiprazole—Thrombocytopenia—Betamethasone—psoriasis	4.52e-05	0.000105	CcSEcCtD
Aripiprazole—Thrombocytopenia—Dexamethasone—psoriasis	4.52e-05	0.000105	CcSEcCtD
Aripiprazole—Tachycardia—Dexamethasone—psoriasis	4.5e-05	0.000105	CcSEcCtD
Aripiprazole—Tachycardia—Betamethasone—psoriasis	4.5e-05	0.000105	CcSEcCtD
Aripiprazole—Angioedema—Prednisone—psoriasis	4.5e-05	0.000105	CcSEcCtD
Aripiprazole—Hypersensitivity—Cyclosporine—psoriasis	4.48e-05	0.000104	CcSEcCtD
Aripiprazole—Dyspepsia—Triamcinolone—psoriasis	4.48e-05	0.000104	CcSEcCtD
Aripiprazole—Nausea—Mycophenolic acid—psoriasis	4.46e-05	0.000104	CcSEcCtD
Aripiprazole—Hyperhidrosis—Betamethasone—psoriasis	4.46e-05	0.000104	CcSEcCtD
Aripiprazole—Hyperhidrosis—Dexamethasone—psoriasis	4.46e-05	0.000104	CcSEcCtD
Aripiprazole—Feeling abnormal—Hydrocortisone—psoriasis	4.45e-05	0.000104	CcSEcCtD
Aripiprazole—Malaise—Prednisone—psoriasis	4.44e-05	0.000103	CcSEcCtD
Aripiprazole—Vertigo—Prednisone—psoriasis	4.42e-05	0.000103	CcSEcCtD
Aripiprazole—Eye disorder—Methotrexate—psoriasis	4.42e-05	0.000103	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Hydrocortisone—psoriasis	4.42e-05	0.000103	CcSEcCtD
Aripiprazole—Syncope—Prednisone—psoriasis	4.42e-05	0.000103	CcSEcCtD
Aripiprazole—Tinnitus—Methotrexate—psoriasis	4.41e-05	0.000103	CcSEcCtD
Aripiprazole—Anorexia—Dexamethasone—psoriasis	4.4e-05	0.000102	CcSEcCtD
Aripiprazole—Anorexia—Betamethasone—psoriasis	4.4e-05	0.000102	CcSEcCtD
Aripiprazole—Urticaria—Prednisolone—psoriasis	4.39e-05	0.000102	CcSEcCtD
Aripiprazole—Cardiac disorder—Methotrexate—psoriasis	4.39e-05	0.000102	CcSEcCtD
Aripiprazole—Fatigue—Triamcinolone—psoriasis	4.38e-05	0.000102	CcSEcCtD
Aripiprazole—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.37e-05	0.000102	CcSEcCtD
Aripiprazole—Asthenia—Cyclosporine—psoriasis	4.36e-05	0.000102	CcSEcCtD
Aripiprazole—Pain—Triamcinolone—psoriasis	4.35e-05	0.000101	CcSEcCtD
Aripiprazole—Loss of consciousness—Prednisone—psoriasis	4.33e-05	0.000101	CcSEcCtD
Aripiprazole—Hypotension—Betamethasone—psoriasis	4.31e-05	0.0001	CcSEcCtD
Aripiprazole—Hypotension—Dexamethasone—psoriasis	4.31e-05	0.0001	CcSEcCtD
Aripiprazole—Pruritus—Cyclosporine—psoriasis	4.3e-05	0.0001	CcSEcCtD
Aripiprazole—Urticaria—Hydrocortisone—psoriasis	4.29e-05	9.99e-05	CcSEcCtD
Aripiprazole—Angiopathy—Methotrexate—psoriasis	4.29e-05	9.99e-05	CcSEcCtD
Aripiprazole—Immune system disorder—Methotrexate—psoriasis	4.27e-05	9.95e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Hydrocortisone—psoriasis	4.27e-05	9.95e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Hydrocortisone—psoriasis	4.27e-05	9.95e-05	CcSEcCtD
Aripiprazole—Convulsion—Prednisone—psoriasis	4.27e-05	9.94e-05	CcSEcCtD
Aripiprazole—Mediastinal disorder—Methotrexate—psoriasis	4.26e-05	9.92e-05	CcSEcCtD
Aripiprazole—Asthenia—Mycophenolate mofetil—psoriasis	4.25e-05	9.91e-05	CcSEcCtD
Aripiprazole—Hypertension—Prednisone—psoriasis	4.25e-05	9.9e-05	CcSEcCtD
Aripiprazole—Chills—Methotrexate—psoriasis	4.24e-05	9.88e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.2e-05	9.79e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Betamethasone—psoriasis	4.2e-05	9.79e-05	CcSEcCtD
Aripiprazole—Pruritus—Mycophenolate mofetil—psoriasis	4.19e-05	9.77e-05	CcSEcCtD
Aripiprazole—Myalgia—Prednisone—psoriasis	4.19e-05	9.76e-05	CcSEcCtD
Aripiprazole—Arthralgia—Prednisone—psoriasis	4.19e-05	9.76e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Triamcinolone—psoriasis	4.19e-05	9.76e-05	CcSEcCtD
Aripiprazole—Anxiety—Prednisone—psoriasis	4.18e-05	9.73e-05	CcSEcCtD
Aripiprazole—Alopecia—Methotrexate—psoriasis	4.18e-05	9.73e-05	CcSEcCtD
Aripiprazole—Insomnia—Betamethasone—psoriasis	4.17e-05	9.72e-05	CcSEcCtD
Aripiprazole—Insomnia—Dexamethasone—psoriasis	4.17e-05	9.72e-05	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4.16e-05	9.7e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Cyclosporine—psoriasis	4.16e-05	9.69e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Dexamethasone—psoriasis	4.14e-05	9.65e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Betamethasone—psoriasis	4.14e-05	9.65e-05	CcSEcCtD
Aripiprazole—Discomfort—Prednisone—psoriasis	4.14e-05	9.65e-05	CcSEcCtD
Aripiprazole—Mental disorder—Methotrexate—psoriasis	4.14e-05	9.65e-05	CcSEcCtD
Aripiprazole—Erythema—Methotrexate—psoriasis	4.12e-05	9.59e-05	CcSEcCtD
Aripiprazole—Malnutrition—Methotrexate—psoriasis	4.12e-05	9.59e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Prednisolone—psoriasis	4.07e-05	9.49e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Dexamethasone—psoriasis	4.06e-05	9.46e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Betamethasone—psoriasis	4.06e-05	9.46e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Mycophenolate mofetil—psoriasis	4.06e-05	9.45e-05	CcSEcCtD
Aripiprazole—Urticaria—Triamcinolone—psoriasis	4.04e-05	9.41e-05	CcSEcCtD
Aripiprazole—Dysgeusia—Methotrexate—psoriasis	4.03e-05	9.39e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Triamcinolone—psoriasis	4.02e-05	9.36e-05	CcSEcCtD
Aripiprazole—Dizziness—Cyclosporine—psoriasis	4.02e-05	9.36e-05	CcSEcCtD
Aripiprazole—Oedema—Prednisone—psoriasis	4.02e-05	9.36e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Prednisone—psoriasis	4.02e-05	9.36e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Dexamethasone—psoriasis	4.01e-05	9.34e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Betamethasone—psoriasis	4.01e-05	9.34e-05	CcSEcCtD
Aripiprazole—Infection—Prednisone—psoriasis	3.99e-05	9.3e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Betamethasone—psoriasis	3.98e-05	9.28e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Dexamethasone—psoriasis	3.98e-05	9.28e-05	CcSEcCtD
Aripiprazole—Back pain—Methotrexate—psoriasis	3.98e-05	9.27e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Hydrocortisone—psoriasis	3.98e-05	9.27e-05	CcSEcCtD
Aripiprazole—Fatigue—Betamethasone—psoriasis	3.98e-05	9.27e-05	CcSEcCtD
Aripiprazole—Fatigue—Dexamethasone—psoriasis	3.98e-05	9.27e-05	CcSEcCtD
Aripiprazole—Shock—Prednisone—psoriasis	3.95e-05	9.21e-05	CcSEcCtD
Aripiprazole—Pain—Betamethasone—psoriasis	3.95e-05	9.19e-05	CcSEcCtD
Aripiprazole—Pain—Dexamethasone—psoriasis	3.95e-05	9.19e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Prednisone—psoriasis	3.94e-05	9.18e-05	CcSEcCtD
Aripiprazole—Tachycardia—Prednisone—psoriasis	3.92e-05	9.14e-05	CcSEcCtD
Aripiprazole—Dizziness—Mycophenolate mofetil—psoriasis	3.92e-05	9.13e-05	CcSEcCtD
Aripiprazole—Skin disorder—Prednisone—psoriasis	3.9e-05	9.09e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Prednisone—psoriasis	3.89e-05	9.05e-05	CcSEcCtD
Aripiprazole—Vision blurred—Methotrexate—psoriasis	3.88e-05	9.03e-05	CcSEcCtD
Aripiprazole—Asthenia—Hydrocortisone—psoriasis	3.88e-05	9.03e-05	CcSEcCtD
Aripiprazole—Vomiting—Cyclosporine—psoriasis	3.86e-05	9e-05	CcSEcCtD
Aripiprazole—Rash—Cyclosporine—psoriasis	3.83e-05	8.93e-05	CcSEcCtD
Aripiprazole—Anorexia—Prednisone—psoriasis	3.83e-05	8.92e-05	CcSEcCtD
Aripiprazole—Dermatitis—Cyclosporine—psoriasis	3.83e-05	8.92e-05	CcSEcCtD
Aripiprazole—Pruritus—Hydrocortisone—psoriasis	3.82e-05	8.9e-05	CcSEcCtD
Aripiprazole—Ill-defined disorder—Methotrexate—psoriasis	3.82e-05	8.89e-05	CcSEcCtD
Aripiprazole—Headache—Cyclosporine—psoriasis	3.81e-05	8.87e-05	CcSEcCtD
Aripiprazole—Anaemia—Methotrexate—psoriasis	3.8e-05	8.86e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Betamethasone—psoriasis	3.8e-05	8.86e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Dexamethasone—psoriasis	3.8e-05	8.86e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Dexamethasone—psoriasis	3.77e-05	8.79e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Betamethasone—psoriasis	3.77e-05	8.79e-05	CcSEcCtD
Aripiprazole—Vomiting—Mycophenolate mofetil—psoriasis	3.77e-05	8.78e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Triamcinolone—psoriasis	3.75e-05	8.73e-05	CcSEcCtD
Aripiprazole—Rash—Mycophenolate mofetil—psoriasis	3.74e-05	8.71e-05	CcSEcCtD
Aripiprazole—Dermatitis—Mycophenolate mofetil—psoriasis	3.73e-05	8.7e-05	CcSEcCtD
Aripiprazole—Headache—Mycophenolate mofetil—psoriasis	3.71e-05	8.65e-05	CcSEcCtD
Aripiprazole—Malaise—Methotrexate—psoriasis	3.71e-05	8.64e-05	CcSEcCtD
Aripiprazole—Vertigo—Methotrexate—psoriasis	3.7e-05	8.61e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Hydrocortisone—psoriasis	3.7e-05	8.61e-05	CcSEcCtD
Aripiprazole—Leukopenia—Methotrexate—psoriasis	3.68e-05	8.58e-05	CcSEcCtD
Aripiprazole—Urticaria—Betamethasone—psoriasis	3.67e-05	8.54e-05	CcSEcCtD
Aripiprazole—Urticaria—Dexamethasone—psoriasis	3.67e-05	8.54e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Prednisone—psoriasis	3.66e-05	8.53e-05	CcSEcCtD
Aripiprazole—Dizziness—Prednisolone—psoriasis	3.66e-05	8.52e-05	CcSEcCtD
Aripiprazole—Asthenia—Triamcinolone—psoriasis	3.65e-05	8.5e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Dexamethasone—psoriasis	3.65e-05	8.5e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Betamethasone—psoriasis	3.65e-05	8.5e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Betamethasone—psoriasis	3.65e-05	8.5e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Dexamethasone—psoriasis	3.65e-05	8.5e-05	CcSEcCtD
Aripiprazole—Insomnia—Prednisone—psoriasis	3.63e-05	8.47e-05	CcSEcCtD
Aripiprazole—Nausea—Cyclosporine—psoriasis	3.61e-05	8.41e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Prednisone—psoriasis	3.61e-05	8.41e-05	CcSEcCtD
Aripiprazole—Pruritus—Triamcinolone—psoriasis	3.6e-05	8.38e-05	CcSEcCtD
Aripiprazole—Cough—Methotrexate—psoriasis	3.59e-05	8.36e-05	CcSEcCtD
Aripiprazole—Dizziness—Hydrocortisone—psoriasis	3.57e-05	8.32e-05	CcSEcCtD
Aripiprazole—Convulsion—Methotrexate—psoriasis	3.57e-05	8.3e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Prednisone—psoriasis	3.54e-05	8.24e-05	CcSEcCtD
Aripiprazole—Nausea—Mycophenolate mofetil—psoriasis	3.52e-05	8.2e-05	CcSEcCtD
Aripiprazole—Chest pain—Methotrexate—psoriasis	3.5e-05	8.16e-05	CcSEcCtD
Aripiprazole—Myalgia—Methotrexate—psoriasis	3.5e-05	8.16e-05	CcSEcCtD
Aripiprazole—Arthralgia—Methotrexate—psoriasis	3.5e-05	8.16e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Prednisone—psoriasis	3.49e-05	8.14e-05	CcSEcCtD
Aripiprazole—Rash—Prednisolone—psoriasis	3.49e-05	8.12e-05	CcSEcCtD
Aripiprazole—Dermatitis—Prednisolone—psoriasis	3.48e-05	8.11e-05	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.48e-05	8.1e-05	CcSEcCtD
Aripiprazole—Fatigue—Prednisone—psoriasis	3.46e-05	8.07e-05	CcSEcCtD
Aripiprazole—Headache—Prednisolone—psoriasis	3.46e-05	8.07e-05	CcSEcCtD
Aripiprazole—Discomfort—Methotrexate—psoriasis	3.46e-05	8.06e-05	CcSEcCtD
Aripiprazole—Constipation—Prednisone—psoriasis	3.44e-05	8e-05	CcSEcCtD
Aripiprazole—Vomiting—Hydrocortisone—psoriasis	3.43e-05	8e-05	CcSEcCtD
Aripiprazole—Rash—Hydrocortisone—psoriasis	3.41e-05	7.93e-05	CcSEcCtD
Aripiprazole—Dermatitis—Hydrocortisone—psoriasis	3.4e-05	7.92e-05	CcSEcCtD
Aripiprazole—Confusional state—Methotrexate—psoriasis	3.39e-05	7.89e-05	CcSEcCtD
Aripiprazole—Headache—Hydrocortisone—psoriasis	3.38e-05	7.88e-05	CcSEcCtD
Aripiprazole—Dizziness—Triamcinolone—psoriasis	3.36e-05	7.83e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Methotrexate—psoriasis	3.36e-05	7.82e-05	CcSEcCtD
Aripiprazole—Infection—Methotrexate—psoriasis	3.34e-05	7.77e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Prednisone—psoriasis	3.31e-05	7.71e-05	CcSEcCtD
Aripiprazole—Asthenia—Dexamethasone—psoriasis	3.31e-05	7.71e-05	CcSEcCtD
Aripiprazole—Asthenia—Betamethasone—psoriasis	3.31e-05	7.71e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Methotrexate—psoriasis	3.29e-05	7.67e-05	CcSEcCtD
Aripiprazole—Thrombocytopenia—Methotrexate—psoriasis	3.29e-05	7.66e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Prednisone—psoriasis	3.29e-05	7.65e-05	CcSEcCtD
Aripiprazole—Nausea—Prednisolone—psoriasis	3.28e-05	7.65e-05	CcSEcCtD
Aripiprazole—Pruritus—Dexamethasone—psoriasis	3.26e-05	7.6e-05	CcSEcCtD
Aripiprazole—Pruritus—Betamethasone—psoriasis	3.26e-05	7.6e-05	CcSEcCtD
Aripiprazole—Skin disorder—Methotrexate—psoriasis	3.26e-05	7.6e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Methotrexate—psoriasis	3.25e-05	7.56e-05	CcSEcCtD
Aripiprazole—Vomiting—Triamcinolone—psoriasis	3.23e-05	7.53e-05	CcSEcCtD
Aripiprazole—Nausea—Hydrocortisone—psoriasis	3.21e-05	7.47e-05	CcSEcCtD
Aripiprazole—Rash—Triamcinolone—psoriasis	3.21e-05	7.47e-05	CcSEcCtD
Aripiprazole—Dermatitis—Triamcinolone—psoriasis	3.2e-05	7.46e-05	CcSEcCtD
Aripiprazole—Anorexia—Methotrexate—psoriasis	3.2e-05	7.46e-05	CcSEcCtD
Aripiprazole—Urticaria—Prednisone—psoriasis	3.19e-05	7.44e-05	CcSEcCtD
Aripiprazole—Headache—Triamcinolone—psoriasis	3.19e-05	7.42e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Prednisone—psoriasis	3.18e-05	7.4e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Prednisone—psoriasis	3.18e-05	7.4e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Betamethasone—psoriasis	3.16e-05	7.35e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Dexamethasone—psoriasis	3.16e-05	7.35e-05	CcSEcCtD
Aripiprazole—Hypotension—Methotrexate—psoriasis	3.14e-05	7.31e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Methotrexate—psoriasis	3.06e-05	7.13e-05	CcSEcCtD
Aripiprazole—Dizziness—Dexamethasone—psoriasis	3.05e-05	7.11e-05	CcSEcCtD
Aripiprazole—Dizziness—Betamethasone—psoriasis	3.05e-05	7.11e-05	CcSEcCtD
Aripiprazole—Insomnia—Methotrexate—psoriasis	3.04e-05	7.08e-05	CcSEcCtD
Aripiprazole—Nausea—Triamcinolone—psoriasis	3.02e-05	7.04e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Methotrexate—psoriasis	3.02e-05	7.02e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Methotrexate—psoriasis	2.99e-05	6.97e-05	CcSEcCtD
Aripiprazole—Somnolence—Methotrexate—psoriasis	2.99e-05	6.95e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Prednisone—psoriasis	2.96e-05	6.9e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Methotrexate—psoriasis	2.96e-05	6.89e-05	CcSEcCtD
Aripiprazole—Vomiting—Betamethasone—psoriasis	2.93e-05	6.83e-05	CcSEcCtD
Aripiprazole—Vomiting—Dexamethasone—psoriasis	2.93e-05	6.83e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Methotrexate—psoriasis	2.92e-05	6.8e-05	CcSEcCtD
Aripiprazole—Rash—Dexamethasone—psoriasis	2.91e-05	6.78e-05	CcSEcCtD
Aripiprazole—Rash—Betamethasone—psoriasis	2.91e-05	6.78e-05	CcSEcCtD
Aripiprazole—Dermatitis—Betamethasone—psoriasis	2.91e-05	6.77e-05	CcSEcCtD
Aripiprazole—Dermatitis—Dexamethasone—psoriasis	2.91e-05	6.77e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Methotrexate—psoriasis	2.9e-05	6.75e-05	CcSEcCtD
Aripiprazole—Fatigue—Methotrexate—psoriasis	2.9e-05	6.74e-05	CcSEcCtD
Aripiprazole—Headache—Betamethasone—psoriasis	2.89e-05	6.73e-05	CcSEcCtD
Aripiprazole—Headache—Dexamethasone—psoriasis	2.89e-05	6.73e-05	CcSEcCtD
Aripiprazole—Asthenia—Prednisone—psoriasis	2.88e-05	6.72e-05	CcSEcCtD
Aripiprazole—Pain—Methotrexate—psoriasis	2.87e-05	6.69e-05	CcSEcCtD
Aripiprazole—Pruritus—Prednisone—psoriasis	2.84e-05	6.62e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Methotrexate—psoriasis	2.77e-05	6.45e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Prednisone—psoriasis	2.75e-05	6.4e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Methotrexate—psoriasis	2.75e-05	6.4e-05	CcSEcCtD
Aripiprazole—Nausea—Dexamethasone—psoriasis	2.74e-05	6.38e-05	CcSEcCtD
Aripiprazole—Nausea—Betamethasone—psoriasis	2.74e-05	6.38e-05	CcSEcCtD
Aripiprazole—Urticaria—Methotrexate—psoriasis	2.67e-05	6.21e-05	CcSEcCtD
Aripiprazole—Dizziness—Prednisone—psoriasis	2.66e-05	6.19e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Methotrexate—psoriasis	2.66e-05	6.18e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Methotrexate—psoriasis	2.66e-05	6.18e-05	CcSEcCtD
Aripiprazole—Vomiting—Prednisone—psoriasis	2.56e-05	5.95e-05	CcSEcCtD
Aripiprazole—Rash—Prednisone—psoriasis	2.53e-05	5.9e-05	CcSEcCtD
Aripiprazole—Dermatitis—Prednisone—psoriasis	2.53e-05	5.9e-05	CcSEcCtD
Aripiprazole—Headache—Prednisone—psoriasis	2.52e-05	5.86e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Methotrexate—psoriasis	2.47e-05	5.76e-05	CcSEcCtD
Aripiprazole—Asthenia—Methotrexate—psoriasis	2.41e-05	5.61e-05	CcSEcCtD
Aripiprazole—Nausea—Prednisone—psoriasis	2.39e-05	5.56e-05	CcSEcCtD
Aripiprazole—Pruritus—Methotrexate—psoriasis	2.38e-05	5.53e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Methotrexate—psoriasis	2.3e-05	5.35e-05	CcSEcCtD
Aripiprazole—Dizziness—Methotrexate—psoriasis	2.22e-05	5.17e-05	CcSEcCtD
Aripiprazole—Vomiting—Methotrexate—psoriasis	2.14e-05	4.97e-05	CcSEcCtD
Aripiprazole—Rash—Methotrexate—psoriasis	2.12e-05	4.93e-05	CcSEcCtD
Aripiprazole—Dermatitis—Methotrexate—psoriasis	2.12e-05	4.93e-05	CcSEcCtD
Aripiprazole—Headache—Methotrexate—psoriasis	2.1e-05	4.9e-05	CcSEcCtD
Aripiprazole—Nausea—Methotrexate—psoriasis	1.99e-05	4.65e-05	CcSEcCtD
Aripiprazole—CHRM3—Metabolism—PPARG—psoriasis	7.79e-06	0.000121	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—CXCL8—psoriasis	7.77e-06	0.000121	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TYK2—psoriasis	7.74e-06	0.00012	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	7.74e-06	0.00012	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	7.71e-06	0.00012	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—LEP—psoriasis	7.66e-06	0.000119	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—APOE—psoriasis	7.66e-06	0.000119	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TYK2—psoriasis	7.64e-06	0.000119	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—CXCL8—psoriasis	7.61e-06	0.000118	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—LEP—psoriasis	7.54e-06	0.000117	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—APOE—psoriasis	7.54e-06	0.000117	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—LEP—psoriasis	7.52e-06	0.000117	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—APOE—psoriasis	7.52e-06	0.000117	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—APOE—psoriasis	7.52e-06	0.000117	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—APOE—psoriasis	7.5e-06	0.000117	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—LEP—psoriasis	7.5e-06	0.000117	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—CXCL8—psoriasis	7.49e-06	0.000116	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—LEP—psoriasis	7.47e-06	0.000116	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—APOE—psoriasis	7.47e-06	0.000116	CbGpPWpGaD
Aripiprazole—HTR6—Signaling by GPCR—IL6—psoriasis	7.45e-06	0.000116	CbGpPWpGaD
Aripiprazole—HTR7—Signaling by GPCR—IL6—psoriasis	7.44e-06	0.000116	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—APOE—psoriasis	7.4e-06	0.000115	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—LEP—psoriasis	7.4e-06	0.000115	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling by GPCR—IL6—psoriasis	7.39e-06	0.000115	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—CXCL8—psoriasis	7.39e-06	0.000115	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—LEP—psoriasis	7.38e-06	0.000115	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—APOE—psoriasis	7.38e-06	0.000115	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CARM1—psoriasis	7.31e-06	0.000114	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—CAT—psoriasis	7.3e-06	0.000113	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—JUN—psoriasis	7.28e-06	0.000113	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—JUN—psoriasis	7.27e-06	0.000113	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling by GPCR—IL6—psoriasis	7.24e-06	0.000112	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—JUN—psoriasis	7.23e-06	0.000112	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—CXCL8—psoriasis	7.15e-06	0.000111	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PPARG—psoriasis	7.14e-06	0.000111	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—NFKBIA—psoriasis	7.14e-06	0.000111	CbGpPWpGaD
Aripiprazole—DRD4—Signaling by GPCR—IL6—psoriasis	7.12e-06	0.000111	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—CXCL8—psoriasis	7.08e-06	0.00011	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—JUN—psoriasis	7.08e-06	0.00011	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—TP53—psoriasis	7.04e-06	0.000109	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling by GPCR—IL6—psoriasis	7.03e-06	0.000109	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—NFKBIA—psoriasis	7.02e-06	0.000109	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—NFKB1—psoriasis	7.01e-06	0.000109	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—NFKBIA—psoriasis	7.01e-06	0.000109	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—NFKB1—psoriasis	7e-06	0.000109	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—NFKBIA—psoriasis	6.99e-06	0.000109	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—NFKBIA—psoriasis	6.96e-06	0.000108	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—JUN—psoriasis	6.96e-06	0.000108	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TYK2—psoriasis	6.96e-06	0.000108	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—NFKB1—psoriasis	6.96e-06	0.000108	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TYK2—psoriasis	6.9e-06	0.000107	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—NFKBIA—psoriasis	6.9e-06	0.000107	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—CAT—psoriasis	6.88e-06	0.000107	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	6.88e-06	0.000107	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—JUN—psoriasis	6.87e-06	0.000107	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—LEP—psoriasis	6.86e-06	0.000107	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—APOE—psoriasis	6.86e-06	0.000107	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—NFKB1—psoriasis	6.81e-06	0.000106	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling by GPCR—IL6—psoriasis	6.8e-06	0.000106	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—CXCL8—psoriasis	6.74e-06	0.000105	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling by GPCR—IL6—psoriasis	6.73e-06	0.000105	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—NFKB1—psoriasis	6.7e-06	0.000104	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TYK2—psoriasis	6.66e-06	0.000103	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—CXCL8—psoriasis	6.65e-06	0.000103	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—JUN—psoriasis	6.65e-06	0.000103	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TYK2—psoriasis	6.63e-06	0.000103	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—NFKB1—psoriasis	6.61e-06	0.000103	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—JUN—psoriasis	6.58e-06	0.000102	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PPARG—psoriasis	6.55e-06	0.000102	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TYK2—psoriasis	6.44e-06	0.0001	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—IL6—psoriasis	6.44e-06	0.0001	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—IL6—psoriasis	6.41e-06	9.96e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—NFKB1—psoriasis	6.4e-06	9.94e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	6.39e-06	9.93e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—VEGFA—psoriasis	6.36e-06	9.89e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—VEGFA—psoriasis	6.36e-06	9.88e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TYK2—psoriasis	6.34e-06	9.86e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—NFKB1—psoriasis	6.33e-06	9.84e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—IL6—psoriasis	6.33e-06	9.83e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—VEGFA—psoriasis	6.31e-06	9.81e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—STAT3—psoriasis	6.3e-06	9.79e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—STAT3—psoriasis	6.29e-06	9.78e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—JUN—psoriasis	6.27e-06	9.74e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—STAT3—psoriasis	6.25e-06	9.72e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—TP53—psoriasis	6.23e-06	9.68e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—JUN—psoriasis	6.19e-06	9.61e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—VEGFA—psoriasis	6.18e-06	9.61e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—STAT3—psoriasis	6.12e-06	9.51e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—VEGFA—psoriasis	6.08e-06	9.45e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—CXCL8—psoriasis	6.06e-06	9.42e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—NFKB1—psoriasis	6.03e-06	9.38e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—STAT3—psoriasis	6.02e-06	9.36e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—CXCL8—psoriasis	6.01e-06	9.33e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—VEGFA—psoriasis	6e-06	9.33e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—NFKB1—psoriasis	5.95e-06	9.25e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—STAT3—psoriasis	5.94e-06	9.24e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TYK2—psoriasis	5.85e-06	9.09e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—VEGFA—psoriasis	5.81e-06	9.03e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CXCL8—psoriasis	5.8e-06	9.01e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CXCL8—psoriasis	5.77e-06	8.96e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—IL6—psoriasis	5.76e-06	8.96e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TYK2—psoriasis	5.75e-06	8.94e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—STAT3—psoriasis	5.75e-06	8.94e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—VEGFA—psoriasis	5.75e-06	8.93e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TYK2—psoriasis	5.74e-06	8.92e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TYK2—psoriasis	5.72e-06	8.89e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—IL6—psoriasis	5.71e-06	8.88e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TYK2—psoriasis	5.7e-06	8.87e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—IL6—psoriasis	5.7e-06	8.86e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—STAT3—psoriasis	5.69e-06	8.84e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—APOE—psoriasis	5.67e-06	8.81e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TYK2—psoriasis	5.65e-06	8.78e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—JUN—psoriasis	5.64e-06	8.76e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TYK2—psoriasis	5.63e-06	8.75e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CXCL8—psoriasis	5.61e-06	8.72e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—JUN—psoriasis	5.58e-06	8.68e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CXCL8—psoriasis	5.52e-06	8.58e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—IL6—psoriasis	5.51e-06	8.57e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—IL6—psoriasis	5.49e-06	8.52e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—VEGFA—psoriasis	5.48e-06	8.51e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—NFKB1—psoriasis	5.42e-06	8.43e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—STAT3—psoriasis	5.42e-06	8.43e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—VEGFA—psoriasis	5.4e-06	8.4e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—JUN—psoriasis	5.39e-06	8.38e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—NFKB1—psoriasis	5.38e-06	8.35e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—JUN—psoriasis	5.36e-06	8.33e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—STAT3—psoriasis	5.35e-06	8.32e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—APOE—psoriasis	5.34e-06	8.31e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—IL6—psoriasis	5.34e-06	8.29e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—IL6—psoriasis	5.25e-06	8.16e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TYK2—psoriasis	5.23e-06	8.13e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—JUN—psoriasis	5.22e-06	8.11e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—NFKB1—psoriasis	5.19e-06	8.06e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—NFKB1—psoriasis	5.16e-06	8.02e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—JUN—psoriasis	5.13e-06	7.98e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CXCL8—psoriasis	5.09e-06	7.91e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—NFKB1—psoriasis	5.02e-06	7.8e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CXCL8—psoriasis	5.01e-06	7.78e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CXCL8—psoriasis	5e-06	7.77e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CXCL8—psoriasis	4.98e-06	7.74e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CXCL8—psoriasis	4.97e-06	7.72e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—NFKB1—psoriasis	4.94e-06	7.68e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PPARG—psoriasis	4.94e-06	7.68e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—VEGFA—psoriasis	4.92e-06	7.65e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CXCL8—psoriasis	4.92e-06	7.64e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CXCL8—psoriasis	4.9e-06	7.62e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—VEGFA—psoriasis	4.88e-06	7.58e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—STAT3—psoriasis	4.88e-06	7.58e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—IL6—psoriasis	4.84e-06	7.52e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—STAT3—psoriasis	4.83e-06	7.51e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—TP53—psoriasis	4.81e-06	7.47e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—TP53—psoriasis	4.8e-06	7.46e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—TP53—psoriasis	4.77e-06	7.41e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—IL6—psoriasis	4.76e-06	7.4e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—IL6—psoriasis	4.75e-06	7.39e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—IL6—psoriasis	4.74e-06	7.36e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—JUN—psoriasis	4.73e-06	7.36e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—IL6—psoriasis	4.72e-06	7.34e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—VEGFA—psoriasis	4.71e-06	7.32e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—VEGFA—psoriasis	4.69e-06	7.28e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—IL6—psoriasis	4.68e-06	7.27e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—TP53—psoriasis	4.67e-06	7.26e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—IL6—psoriasis	4.66e-06	7.25e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—STAT3—psoriasis	4.66e-06	7.25e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—JUN—psoriasis	4.66e-06	7.24e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PPARG—psoriasis	4.66e-06	7.23e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—JUN—psoriasis	4.65e-06	7.22e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—STAT3—psoriasis	4.64e-06	7.21e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—JUN—psoriasis	4.63e-06	7.2e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—JUN—psoriasis	4.62e-06	7.18e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—TP53—psoriasis	4.6e-06	7.14e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—JUN—psoriasis	4.57e-06	7.11e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—JUN—psoriasis	4.56e-06	7.09e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CXCL8—psoriasis	4.56e-06	7.08e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—VEGFA—psoriasis	4.56e-06	7.08e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—NFKB1—psoriasis	4.56e-06	7.08e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—TP53—psoriasis	4.53e-06	7.05e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—STAT3—psoriasis	4.51e-06	7.01e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CAT—psoriasis	4.5e-06	6.99e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—VEGFA—psoriasis	4.48e-06	6.97e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—NFKB1—psoriasis	4.48e-06	6.97e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—NFKB1—psoriasis	4.47e-06	6.95e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—NFKB1—psoriasis	4.46e-06	6.93e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—NFKB1—psoriasis	4.44e-06	6.91e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—STAT3—psoriasis	4.44e-06	6.9e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—NFKB1—psoriasis	4.4e-06	6.84e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—IL6—psoriasis	4.4e-06	6.84e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—IL6—psoriasis	4.4e-06	6.83e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—NFKB1—psoriasis	4.39e-06	6.82e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—psoriasis	4.39e-06	6.82e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—IL6—psoriasis	4.37e-06	6.79e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—psoriasis	4.34e-06	6.75e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—IL6—psoriasis	4.33e-06	6.73e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—IL6—psoriasis	4.28e-06	6.64e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—JUN—psoriasis	4.24e-06	6.58e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—IL6—psoriasis	4.21e-06	6.54e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—IL6—psoriasis	4.15e-06	6.45e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—psoriasis	4.14e-06	6.43e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—VEGFA—psoriasis	4.13e-06	6.43e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—STAT3—psoriasis	4.09e-06	6.36e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—psoriasis	4.08e-06	6.35e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—NFKB1—psoriasis	4.08e-06	6.34e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—VEGFA—psoriasis	4.07e-06	6.32e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—VEGFA—psoriasis	4.06e-06	6.31e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—VEGFA—psoriasis	4.05e-06	6.29e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—VEGFA—psoriasis	4.03e-06	6.27e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—STAT3—psoriasis	4.03e-06	6.26e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—STAT3—psoriasis	4.02e-06	6.25e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—IL6—psoriasis	4.02e-06	6.24e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—STAT3—psoriasis	4.01e-06	6.23e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—VEGFA—psoriasis	3.99e-06	6.21e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—STAT3—psoriasis	3.99e-06	6.21e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—VEGFA—psoriasis	3.98e-06	6.19e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—IL6—psoriasis	3.98e-06	6.18e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—STAT3—psoriasis	3.96e-06	6.15e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—STAT3—psoriasis	3.94e-06	6.13e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—IL6—psoriasis	3.79e-06	5.89e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—IL6—psoriasis	3.74e-06	5.81e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—psoriasis	3.72e-06	5.78e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—VEGFA—psoriasis	3.7e-06	5.75e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—psoriasis	3.69e-06	5.73e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—STAT3—psoriasis	3.67e-06	5.7e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—psoriasis	3.56e-06	5.53e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—psoriasis	3.54e-06	5.5e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—APOE—psoriasis	3.49e-06	5.43e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—psoriasis	3.44e-06	5.35e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—IL6—psoriasis	3.41e-06	5.29e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—psoriasis	3.39e-06	5.27e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—IL6—psoriasis	3.37e-06	5.24e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—IL6—psoriasis	3.26e-06	5.06e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—IL6—psoriasis	3.24e-06	5.04e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—IL6—psoriasis	3.15e-06	4.9e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—psoriasis	3.12e-06	4.86e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—IL6—psoriasis	3.1e-06	4.82e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—psoriasis	3.07e-06	4.78e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—psoriasis	3.07e-06	4.77e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—psoriasis	3.06e-06	4.75e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—psoriasis	3.05e-06	4.74e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PPARG—psoriasis	3.04e-06	4.73e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—psoriasis	3.02e-06	4.69e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—psoriasis	3.01e-06	4.68e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—IL6—psoriasis	2.86e-06	4.44e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—IL6—psoriasis	2.81e-06	4.37e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—IL6—psoriasis	2.81e-06	4.36e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—IL6—psoriasis	2.8e-06	4.35e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—psoriasis	2.8e-06	4.35e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—IL6—psoriasis	2.79e-06	4.34e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—IL6—psoriasis	2.76e-06	4.29e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—IL6—psoriasis	2.76e-06	4.28e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL6—psoriasis	2.56e-06	3.98e-05	CbGpPWpGaD
